Literature DB >> 23465042

Evaluation of self-esteem and depression symptoms in depressed and nondepressed subjects treated with onabotulinumtoxinA for glabellar lines.

Doris Hexsel1, Cristiano Brum, Carolina Siega, Juliana Schilling-Souza, Taciana Dal'Forno, Marc Heckmann, Ticiana C Rodrigues.   

Abstract

BACKGROUND: Botulinum toxin type A (BoNT-A) injection has become the most popular cosmetic nonsurgical procedure, and it has been suggested that BoNT-A injections may improve emotional states when frown lines are treated.
OBJECTIVES: To evaluate symptoms of depression and self-esteem before and after onabotulinumtoxinA (ONA) injections in the glabella in subjects with and without depression.
METHODS: Twenty-five subjects with depression were allocated into one group and 25 subjects without depression were matched to those according to demographic characteristics. The Beck Depression Inventory (BDI) and Rosenberg Self-Esteem Scale (RSES) were used to assess depression symptoms and self-esteem, respectively. Patients were assessed up to 12 weeks after the intervention.
RESULTS: Patients with depression had significant improvement in depression symptoms after ONA injections. The maximum effect occurred within the first 8 weeks after treatment. A significant reduction from baseline in BDI score and significant improvement in self-esteem were also observed in patients with depression.
CONCLUSION: This research presents new data regarding BoNT-A as a potential treatment to improve depression symptoms in patients with Major Depressive Disorder. Self-esteem scores alone cannot explain the improvement in depression symptoms.
© 2013 by the American Society for Dermatologic Surgery, Inc. Published by Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23465042     DOI: 10.1111/dsu.12175

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  13 in total

Review 1.  Treatment of Depression with Botulinum Toxin.

Authors:  Marc Axel Wollmer; Michelle Magid; Tillmann H C Kruger; Eric Finzi
Journal:  Toxins (Basel)       Date:  2022-05-31       Impact factor: 5.075

2.  A multi-lab test of the facial feedback hypothesis by the Many Smiles Collaboration.

Authors:  Nicholas A Coles; David S March; Fernando Marmolejo-Ramos; Jeff T Larsen; Nwadiogo C Arinze; Izuchukwu L G Ndukaihe; Megan L Willis; Francesco Foroni; Niv Reggev; Aviv Mokady; Patrick S Forscher; John F Hunter; Gwenaël Kaminski; Elif Yüvrük; Aycan Kapucu; Tamás Nagy; Nandor Hajdu; Julian Tejada; Raquel M K Freitag; Danilo Zambrano; Bidisha Som; Balazs Aczel; Krystian Barzykowski; Sylwia Adamus; Katarzyna Filip; Yuki Yamada; Ayumi Ikeda; Daniel L Eaves; Carmel A Levitan; Sydney Leiweke; Michal Parzuchowski; Natalie Butcher; Gerit Pfuhl; Dana M Basnight-Brown; José A Hinojosa; Pedro R Montoro; Lady G Javela D; Kevin Vezirian; Hans IJzerman; Natalia Trujillo; Sarah D Pressman; Pascal M Gygax; Asil A Özdoğru; Susana Ruiz-Fernandez; Phoebe C Ellsworth; Lowell Gaertner; Fritz Strack; Marco Marozzi; Marco Tullio Liuzza
Journal:  Nat Hum Behav       Date:  2022-10-20

3.  [Body experience and self-esteem after minimally invasive skin rejuvenation : Study of female patients using botulinum toxin A and/or dermal fillers].

Authors:  D Scharschmidt; S Preiß; E Brähler; T Fischer; A Borkenhagen
Journal:  Hautarzt       Date:  2017-12       Impact factor: 0.751

4.  Personality Disorders among Individuals Seeking Cosmetic Botulinum Toxin Type A (BoNTA) Injection, a Cross-Sectional Study.

Authors:  Alireza Mohebbipour Loron; Azra Ghaffari; Negin Poursafargholi
Journal:  Eurasian J Med       Date:  2018-10

5.  Botulinum toxin-induced facial muscle paralysis affects amygdala responses to the perception of emotional expressions: preliminary findings from an A-B-A design.

Authors:  M Justin Kim; Maital Neta; F Caroline Davis; Erika J Ruberry; Diana Dinescu; Todd F Heatherton; Mitchell A Stotland; Paul J Whalen
Journal:  Biol Mood Anxiety Disord       Date:  2014-10-31

6.  Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy.

Authors:  Simona Guerzoni; Lanfranco Pellesi; Carlo Baraldi; Michela Maria Cainazzo; Andrea Negro; Paolo Martelletti; Luigi Alberto Pini
Journal:  Front Neurol       Date:  2017-11-03       Impact factor: 4.003

Review 7.  High efficacy of onabotulinumtoxinA treatment in patients with comorbid migraine and depression: a meta-analysis.

Authors:  Oreste Affatato; Thiago C Moulin; Claudia Pisanu; Victoria S Babasieva; Marco Russo; Elif I Aydinlar; Paola Torelli; Vladimir N Chubarev; Vadim V Tarasov; Helgi B Schiöth; Jessica Mwinyi
Journal:  J Transl Med       Date:  2021-03-31       Impact factor: 5.531

8.  Agitation predicts response of depression to botulinum toxin treatment in a randomized controlled trial.

Authors:  M Axel Wollmer; Nadeem Kalak; Stefanie Jung; Claas de Boer; Michelle Magid; Jason S Reichenberg; Serge Brand; Edith Holsboer-Trachsler; Tillmann H C Kruger
Journal:  Front Psychiatry       Date:  2014-03-31       Impact factor: 4.157

Review 9.  "Masking" our emotions: Botulinum toxin, facial expression, and well-being in the age of COVID-19.

Authors:  Mark S Nestor; Daniel L Fischer; David Arnold
Journal:  J Cosmet Dermatol       Date:  2020-07-12       Impact factor: 2.189

10.  The interactions between botulinum-toxin-based facial treatments and embodied emotions.

Authors:  Michael B Lewis
Journal:  Sci Rep       Date:  2018-10-03       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.